Arcturus Therapeutics Holdings

ARCT · NASDAQ

$10.98+$0.56 (+5.37%)TodayMarket closed · Oct 20, 7:48 PM ET

Prev close $10.42

Latest news

NewsOct 14, 6:10 AM ET
Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call
NewsOct 9, 10:51 AM ETAvi Kapoor
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
NewsSep 24, 2:26 PM ETVandana Singh
Why Is Arcturus Therapeutics Stock Gaining Thursday?
NewsSep 24, 10:01 AM ETAvi Kapoor
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
Press releaseSep 23, 4:01 PM ETBusiness Wire
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Press releaseSep 18, 9:00 AM ETBusiness Wire
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
NewsSep 11, 8:04 AM ETAvi Kapoor
National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
NewsSep 1, 1:07 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseAug 31, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
NewsAug 21, 1:06 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsAug 20, 8:18 AM ETRadhika Anilkumar Nadig
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)
NewsAug 19, 8:07 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseAug 6, 4:01 PM ETBusiness Wire
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Press releaseJul 28, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
Press releaseJul 20, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
NewsJul 2, 11:32 AM ETVandana Singh
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
Press releaseJul 2, 7:00 AM ETBusiness Wire
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Press releaseMay 26, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
NewsMay 7, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMay 7, 4:01 PM ETBusiness Wire
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Press releaseApr 27, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Press releaseApr 20, 8:30 AM ETGlobe Newswire
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
NewsMar 5, 5:01 PM ET
Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews
Press releaseMar 5, 9:00 AM ETBusiness Wire
Arcturus Therapeutics to Attend Upcoming Investor Conference
Press releaseMar 3, 4:01 PM ETBusiness Wire
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Press releaseFeb 17, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Press releaseJan 8, 5:30 PM ETBusiness Wire
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseNov 24, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Attend Upcoming Investor Conference
Press releaseNov 10, 4:01 PM ETBusiness Wire
Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
Press releaseNov 10, 2:40 PM ETPRNewswire
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
NewsNov 7, 1:05 PM ET
Preview: Arcturus Therapeutics's Earnings
Press releaseNov 4, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Press releaseOct 28, 4:01 PM ETBusiness Wire
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025
Press releaseOct 28, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
NewsOct 22, 1:13 PM ETAvi Kapoor
Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results
NewsOct 22, 10:12 AM ETAvi Kapoor
Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings
Press releaseSep 15, 8:30 AM ETPRNewswire
Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call

Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday

Why Is Arcturus Therapeutics Stock Gaining Thursday?

Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday

Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Arcturus Therapeutics to Participate in Upcoming Investor Conferences

12 Health Care Stocks Moving In Friday's Intraday Session

Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026

Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy

Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis

Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

12 Health Care Stocks Moving In Thursday's After-Market Session

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews

Arcturus Therapeutics to Attend Upcoming Investor Conference

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Arcturus Therapeutics to Attend Upcoming Investor Conference

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm

Preview: Arcturus Therapeutics's Earnings

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT

Crude Oil Gains Over 1%; AT&T Shares Slide After Q3 Results

Dow Falls 100 Points; Netflix Shares Tumble On Downbeat Earnings

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth